Manifestations of blistering diseases in the oral cavity

Czech version

Authors: V. Radochová; R. Slezák
Authors‘ workplace: Přednosta: doc. MUDr. Radovan Slezák, CSc. ; Lékařská fakulta Univerzity Karlovy a Fakultní nemocnice, Hradec Králové Stomatologická klinika
Published in: Prakt. Lék. 2023; 103(6): 280-287
Category: Various Specialization

Overview

The oral mucosa can be affected by many diseases of different origin, nature and severity. These diseases can becompletely benign or serious, including malignant tumors. One group of diseases with manifestations in the oral cavity are vesicular diseases of autoimmune origin, also known as mucocutaneous diseases. These are manifested in the oral cavity primarily by the formation of blisters, which soon rupture and disappear, turning into mucosal defects – erosions to ulcerations, accompanied by variously intense subjective discomfort. These diseases usually have a subacute course and are not accompanied by general symptoms such as fever, reactive inflammation or enlarged regional lymph nodes. On the other hand, they are quite often accompanied by prolonged, restricted food intake and associated with significant weight loss over a relatively short period of several months.

The mucosa of the oral cavity is often the first site of the manifestations of autoimmune blistering mucocutaneous diseases, preceding the involvement of the skin, including the hair, and other mucous membranes (conjunctiva, nasal cavity, pharynx, larynx, esophagus, genitalia and anus). In some cases, oral mucosal involvement is the onlymanifestation of the disease. Diagnosis of these diseases is often late, as their clinical picture may be confused with other mucosal defects of different origin, such as recurrent aphthae, erythema multiforme, viral and fungal diseases,and squamous cell carcinomas of the oral mucosa, due to less than optimal knowledge of the subject. However, early diagnosis of the initial manifestations of these diseases is very important for their prognosis and therapy.

Keywords:

autoimmune diseases – oral mucosa – mucocutaneous diseases – blistering diseases

Sources

Waschke J, Spindler V. Desmosomes and extradesmosomal adhesive signaling contacts in pemphigus. Med Res Rev 2014; 34(6): 1127–1145.
Meyer N, Misery L. Geoepidemiologic considerations of auto– immune pemphigus. Autoimmun Rev 2010; 9(5): A379–382.
Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2012; 11(3): 226–230.
Amber KT, Valdebran M, Grando SA. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplasticpemphigus. Autoimmun Rev 2018; 17(10): 1002–1010.
Rashid H, Lamberts A, Diercks GFH, et al. Oral lesions in autoimmune bullous diseases: an overview of clinical characteristics and diagnosticalgorithm. Am J Clin Dermatol 2019; 20(6): 847–861.
Leuci S, Ruoppo E, Adamo D, et al. Oral autoimmune vesicobullous diseases: Classification, clinical presentations, molecular mechanisms, diagnostic algorithms, and management. Periodontol 2019; 80(1): 77–88.
Cheng SW, Kobayashi M, Kinoshita-Kuroda K, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147(2): 261–265.
McMillan R, Taylor J, Shephard M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120(2): 132–142.e61.
Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the europeanacademy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol 2020; 34(9): 1900–1913.
Antiga E, Bech R, Maglie R, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2023; 37(6): 1118–1134.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381(9863): 320–332.
Di Zenzo G, Carrozzo M, Chan LS. Urban legend series: mucous membrane pemphigoid. Oral Dis 2014; 20(1): 35–54.
Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43(4): 571–591; quiz 591–594.
Hegazy S, Bouchouicha S, Khaled A, et al. IgA pemphigus showing IgA antibodies to desmoglein 1 and 3. Dermatol Pract Concept 2016; 6(4): 31–33.
Shi L, Li X, Qian H. Anti-laminin 332-type mucous membrane pemphigoid. Biomolecules 2022; 12(10): 1461.
Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intraand extracellulardomains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145(5): 778–783.
Carey B, Setterfield J. Mucous membrane pemphigoid and oral blistering diseases. Clin Exp Dermatol 2019; 44(7): 732–739.
Baffa ME, Corrà A, Maglie R, et al. Rituximab in mucous membrane pemphigoid: a monocentric retrospective study in 10 patients with severe/refractory disease. J Clin Med 2022; 11(14): 4102.
Sami N, Letko E, Androudi S, et al. Intravenous immunoglobulin therapy in patients with ocular–cicatricial pemphigoid: a longterm follow-up. Ophthalmology 2004; 111(7): 1380–1382.
Mimouni D, Nousari HC. Bullous pemphigoid. Dermatol Ther 2002; 15(4): 369–373.
Ludwig RJ, Kalies K, Köhl J, et al. Emerging treatments for pemphigoid diseases. Trends Mol Med 2013; 19(8): 501–512.
Fortuna G, Marinkovich MP. Linear immunoglobulin A bullous dermatosis. Clin Dermatol 2012; 30(1): 38–50.
He J, Shen J, Guo W. An unusual case of linear IgA disease affecting only the oral gingiva: a case report. BMC Oral Health 2023; 23(1):541.
Hashimoto T, Yamagami J, Zone JJ. History, diagnosis, pathogenesis, and nomenclature in sublamina densa-type linear IgA disease. JAMA Dermatol 2021; 157(8): 907–909.
Khan M, Park L, Skopit S. Management options for linear immunoglobulin a (IgA) bullous dermatosis: a literature review. Cureus 2023; 15(3): e36481.
DeAngelis LM, Cirillo N, McCullough MJ. The immunopathogenesis of oral lichen planus–Is there a role for mucosal associated invariant T cells? J Oral Pathol Med 2019; 48(7): 552–559.
Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13(4): 350–365.
Farhi D, Dupin N. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol 2010; 28(1): 100–108.
González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, et al. Worldwide prevalence of oral lichen planus: a systematic review and meta-analysis. Oral Dis 2021; 27(4): 813–828.
Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg 2008; 46(1): 15–21.
Radochová V, Koberová Ivančaková R, Heneberk O, Slezák R. The characteristics of patients with oral lichen planus and malignant transformation – a retrospective study of 271 patients. Int J Environ Res Public Health 2021; 18(12): 6525.
Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol 2009; 58(10): 519–537.
Radochová V, Slezák R, Koberová Ivančaková R. Analysis of coexistence of oral and cutaneous lesions in 253 patients with lichen planus – single-center retrospective analysis. Acta Dermatovenerol Croat 2021; 291(1): 1–7.
Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005; 11(6): 338–349.
Carrozzo M, Porter S, Mercadante V, Fedele S. Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes,diagnostic algorhythms, prognosis, management strategies. Periodontol 2000 2019; 80(1): 105–125.
González-Moles MÁ, Warnakulasuriya S, González-Ruiz I, et al. Clinicopathological and prognostic characteristics of oral squamous cell carcinomas arising in patients with oral lichen planus: A systematic review and a comprehensive meta-analysis. Oral Oncol 2020; 106: 104688.
Warnakulasuriya S. White, red, and mixed lesions of oral mucosa: A clinicopathologic approach to diagnosis. Periodontol 2000 2019; 80(1): 89–104.

adresa pro korespondenci:
doc. MUDr. Vladimíra Radochová, Ph.D.
Stomatologická klinika LF UK a FN
Sokolská 581, 500 05 Hradec Králové
e-mail: vladimira.radochova@lfhk.cuni.cz

Labels

General practitioner for children and adolescents General practitioner for adults

The analysis of the relationship between dementia and atherosclerosis risk factors

Topical application of a medicinal preparation with β-glucan

Changes in metallothionein levels in patients with malignant prostate cancer – a pilot study

Oral xenogenic immunomodulating peptide – transfer factor

Intoxication by Cherry Laurel

Intoxication from Wall germander (Teucrium chamaedrys) after consuming a tea after recommendation from herbalist – risks of phytotherapy

Co zvyšuje riziko vzniku psychotického onemocnění po zneužívání kanabis

Article was published in

General Practitioner

2023 Issue 6